Common Cold Clinical Trial
Official title:
A Multicentre, Randomised, Open Label, Parallel Group, Controlled Clinical Trial to Evaluate Efficacy and Tolerability of Two Seawater-based Formulations Plus a Standard of Care Versus the Standard of Care Alone for Relief of Nasal Congestion in Paediatric Subjects With Common Cold
The objective of this clinical trial is to evaluate the tolerance and efficacy of two Stérimar nasal sprays products in children who have nasal congestion due to the common cold.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Months to 48 Months |
Eligibility | Inclusion Criteria: 1. Male and female infants and toddlers aged 3 - 48 months (inclusive) at enrolment (Day 0). 2. Caretaker(s) answering "yes" to the question "Do you feel that your child has a cold?" at enrolment (Day 0). 3. Subjects with symptoms started within 48 hours prior to enrolment (Day 0). 4. Subjects with nasal congestion (blocked / stuffy nose) rated as at least grade 2 (moderately bothersome) on a 0 to 2-point scale, based on morning evaluation (within an hour of subject awakening). 5. Subjects showing at least grade 2 on a 0 to 2-point scale for at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough. 6. Legal caretaker(s) signed written informed consent for their young ones to participate in the study. 7. Legal caretaker(s) willing to comply with all study procedures. 8. Ability of the caretaker(s) (in the Investigator's opinion) to comprehend the full nature, procedures, and purpose of the study. Exclusion Criteria: 1. Subjects presenting a body temperature greater than 38°C measured with a non-contact infrared thermometer at enrolment (Day 0). 2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, and so on) at enrolment (Day 0). 3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at enrolment (Day 0). 4. Subjects with history of allergic rhinitis. 5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, and so on). 6. Subjects presenting any kind of immunodeficiency. 7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products. 8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0). 9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. 10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0). 11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing = 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening. |
Country | Name | City | State |
---|---|---|---|
Italy | San Paolo Hospital | Milan |
Lead Sponsor | Collaborator |
---|---|
Church & Dwight Company, Inc. | Evidilya S.r.l. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Onset of relief. | Assessment of onset of relief (immediate relief) after the entire product application is completed (1 or 2 sprays) at Day 0 (baseline) and daily from Day 1 to Day 3 of the study; comparisons within groups A and B. | Through study completion, an average of 10 days | |
Other | Concomitant medications. | Assessment of use of concomitant medications (frequency, excluding paracetamol) will be done from the beginning to the end of the study; comparisons among groups A, B, C. | Through study completion, an average of 10 days | |
Other | Frequency of paracetamol administration. | Assessment of use of paracetamol (frequency) will be done from the beginning to the end of the study; comparisons within groups A, B, versus group C. | Through study completion, an average of 10 days | |
Other | Quality of sleep. | Assessment of quality of sleep will be evaluated by means of the "quality of sleep" questionnaire, to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons within groups A, B versus group C. | Through study completion, an average of 10 days | |
Other | Global assessment on common cold status. | Global assessment on common cold status will be evaluated by means of the "global assessment on common cold status" questionnaire, to be completed from the beginning to the end of the study; comparisons within groups. | Through study completion, an average of 10 days | |
Primary | Change of nasal congestion. | Assess change of nasal congestion, evaluated by means of a specific questionnaire ("Cold Symptom Severity" questionnaire), to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons among groups A, B versus group C. | Through study completion, an average of 10 days | |
Secondary | Change of other cold symptoms. | Assess change of other cold symptoms, evaluated by means of a specific questionnaire ("Cold Symptom Severity" questionnaire), to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons among groups; comparisons among groups A, B versus group C.
Other cold symptoms: Nasal crust (dry mucus) Runny nose (drip/sniff/snorting/drainage/discharge) Thick mucus Sneezing Cough. |
Through study completion, an average of 10 days | |
Secondary | Occurrence of secondary infections. | Assessment of occurrence of secondary infections (number) daily, from the beginning to the end of the study; comparisons of group A, B versus group C. Secondary infections will be confirmed by the Investigator. | Daily through the end of the study, approximately 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT02451163 -
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly
|
Phase 2 | |
Completed |
NCT01944631 -
Iota-Carrageenan Nasal Spray in Common Cold
|
Phase 4 | |
Completed |
NCT01651715 -
Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections
|
Phase 1/Phase 2 | |
Completed |
NCT00963443 -
Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold
|
Phase 3 | |
Completed |
NCT00778648 -
Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
|
N/A | |
Completed |
NCT00065715 -
Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
|
Phase 3 | |
Completed |
NCT00032500 -
Evaluation of Echinacea for the Common Cold
|
Phase 2 | |
Not yet recruiting |
NCT05070650 -
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
|
Phase 3 | |
Not yet recruiting |
NCT04073511 -
Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold
|
N/A | |
Completed |
NCT04144491 -
Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda
|
N/A | |
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01277081 -
Effect of Paracetamol on the Common Cold
|
Phase 2 | |
Completed |
NCT01728090 -
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
|
Phase 4 | |
Completed |
NCT00405509 -
The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
|
N/A | |
Completed |
NCT01033526 -
Symptomatic Treatment of Common Cold Symptoms
|
Phase 4 | |
Completed |
NCT05556148 -
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
|
Phase 4 | |
Terminated |
NCT03339726 -
Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold
|
Phase 2 | |
Completed |
NCT01361399 -
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
|
Phase 3 |